Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.

MLA

Decara, Juan, et al. “Antiobesity Efficacy of GLP-1 Receptor Agonist Liraglutide Is Associated with Peripheral Tissue-Specific Modulation of Lipid Metabolic Regulators.” BioFactors (Oxford, England), vol. 42, no. 6, Nov. 2016, pp. 600–11. EBSCOhost, https://doi.org/10.1002/biof.1295.

APA

Decara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2016). Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators. BioFactors (Oxford, England), 42(6), 600–611. https://doi.org/10.1002/biof.1295

Chicago

Decara, Juan, Sergio Arrabal, Daniel Beiroa, Patricia Rivera, Antonio Vargas, Antonia Serrano, Francisco Javier Pavón, et al. 2016. “Antiobesity Efficacy of GLP-1 Receptor Agonist Liraglutide Is Associated with Peripheral Tissue-Specific Modulation of Lipid Metabolic Regulators.” BioFactors (Oxford, England) 42 (6): 600–611. doi:10.1002/biof.1295.